Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tg Therapeutics (TGTX)

Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Tg Therapeutics 3020 CARRINGTON MILL BLVD SUITE 475 MORRISVILLE NC 27560 USA

www.tgtherapeutics.com Employees: 338 P: 877-575-8489

Sector:

Medical

Description:

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.

Key Statistics

Overview:

Market Capitalization, $K 4,640,526
Enterprise Value, $K 4,705,066
Shares Outstanding, K 158,759
Float, K 141,867
% Float 89.36%
Short Interest, K 28,950
Short Float 18.23%
Days to Cover 17.58
Short Volume Ratio 0.50
% of Insider Shareholders 10.64%
% of Institutional Shareholders 58.58%

Financials:

Annual Sales, $ 329,000 K
Annual Net Income, $ 23,380 K
Last Quarter Sales, $ 161,710 K
Last Quarter Net Income, $ 390,900 K
EBIT, $ 102,780 K
EBITDA, $ 98,070 K

Growth:

1-Year Return -6.19%
3-Year Return 86.18%
5-Year Return -33.22%
5-Year Revenue Growth 219,233.33%
5-Year Earnings Growth 108.20%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 2.43 on 11/03/25
Next Earnings Date 03/02/26 [--]
Earnings Per Share ttm 2.78
EPS Growth vs. Prev Qtr 1,329.41%
EPS Growth vs. Prev Year 12,050.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-56 on 04/27/12

TGTX Ratios

Ratio
Price/Earnings ttm 10.45
Price/Earnings forward 17.27
Price/Earnings to Growth N/A
Return-on-Equity % 133.25%
Return-on-Assets % 60.43%
Profit Margin % 7.11%
Debt/Equity 0.40
Price/Sales 8.88
Price/Cash Flow 237.57
Price/Book 7.45
Book Value/Share 3.83
Interest Coverage 2.06
60-Month Beta 1.85
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar